ERAP1 Inhibitors for Uveitis Treatment and Genotype Tailoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for uveitis, such as anterior uveitis, are inadequate in managing the condition effectively, and there is a need for methods to identify subjects at increased risk of developing uveitis.
Innovation Solution
Administering ERAP1 inhibitors to subjects with uveitis, and using genetic analysis to determine the presence of ERAP1 variant nucleic acid molecules to tailor treatment dosages based on the subject's genotype.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for uveitis are used, then treatment is provided to subjects, but the treatments are inadequate in managing the condition effectively
Solution Approach 1:
The patent applies local quality by tailoring the treatment approach to specific genetic subgroups of patients. Subjects with ERAP1 reference genotype receive standard treatment, while subjects with ERAP1 variant genotypes receive modified treatment regimens. This localized approach to treatment personalization based on genetic characteristics resolves the contradiction by making treatment both effective and adaptable to individual patient needs.
Solution Approach 2:
The patent implements parameter changes by modifying treatment parameters (dosage, duration, or type of therapy) based on the patient's ERAP1 genotype status. The treatment protocol is adjusted according to the genetic parameter, allowing the same therapeutic agent to be optimized for different genetic backgrounds, thereby improving both effectiveness and adaptability simultaneously.
2Adaptability or versatility
If genetic analysis is performed to identify ERAP1 variants, then personalized treatment can be provided, but the complexity of the treatment protocol increases
Solution Approach 1:
The patent applies segmentation by dividing the patient population into distinct genetic subgroups based on ERAP1 genotype (reference vs. variant carriers). This segmentation simplifies the overall treatment protocol by creating clear, discrete treatment pathways for each subgroup, making the personalized approach more manageable and less complex than a fully continuous customization model.
Solution Approach 2:
The patent uses genetic testing for ERAP1 variants as an intermediary tool that bridges the gap between standard treatment and fully personalized medicine. This intermediary test provides a simple, binary classification (variant present or absent) that guides treatment selection, reducing the complexity that would otherwise arise from more complex personalization algorithms while still enabling adaptable treatment decisions.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The administration of ERAP1 inhibitors effectively treats uveitis, and genetic analysis allows for personalized treatment approaches, reducing the risk of uveitis development in subjects with ERAP1 variant nucleic acid molecules.
Implementation Method 1
Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) is an aminopeptidase involved in trimming of HLA class I-binding precursors
Data Source
AI summary
The present disclosure provides methods of treating subjects having uveitis, and methods of identifying subjects having an increased risk of developing uveitis.